Full Text View
Tabular View
No Study Results Posted
Related Studies
Investigation of Efficacy and Safety of EPOGAM
This study has been completed.
Study NCT00878670   Information provided by Max Zeller Soehne AG

First Received on April 8, 2009.   Last Updated on January 25, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Atopic Dermatitis
Neurodermatitis
Additional conditions recognized in this trial
Dermatitis
Dermatitis, Atopic
More general conditions related to this trial
Genetic Diseases, Inborn
Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Skin Diseases
Skin Diseases, Eczematous
Skin Diseases, Genetic
Interventions listed in this trial
EPOGAM 1000
Additional drug interventions recognized in this trial
Efamol
More general drug interventions related to this trial
Analgesics
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antimetabolites
Antirheumatic Agents
Central Nervous System Agents
Dermatologic Agents
Hypolipidemic Agents
Lipid Regulating Agents
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
Max Zeller Soehne AG


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services